Table 11

Characteristics of exenatide placebo-controlled trials in adults with type 2 diabetes

Author, year
Country
Quality
Sample size (N)
Follow- up (weeks)
Age (years) (SD)a
% Malea
% Whitea
% Hispanica
Duration of diabetes (years)a
Baseline
A1c (%) (SD)a
Weight (kg)a
BMI (kg/m2)a
InterventionCombination therapy
Buse, 2004
101 sites in US
Fair
377
30
55 (10–11)
57–63
59.7–66.7
18.4–21.7
5.7–6.6 (4.7–6.6)
8.5–8.7 (1.1–1.2)
95–99(18–22)
33–34 (5–6)
5, 10 mcg BIDMaximum SU (but could be decreased by 50% based on hypoglycemic events)
DeFronzo, 2005
82 sites in US
Fair
336
30
52–54 (9–11)
51.8–60.2
72.6–79.6
7.3–10.6
4.9–6.6 (4.7–6.1)
8.2–8.3 (1.0–1.1)
100–101(19–22)
34 (6)
5, 10 mcg BIDHigh dose MET
Kendall, 2005
91 sites in US
Fair
733
30
55–56 (9–10)
55.9–59.3
66.4–69.0
15.8–16.6
8.7–9.4 (5.9–6.4)
8.5 (1.0–1.1)
97–99(19–21)
33–34 (5–6)
5, 10 mcg BIDHigh dose MET + SU
Zinman, 2007
49 sites in Canada, Spain, US
Fair
233
16
55.6–56.6 (10.2–10.8)
53.7–57.1
82.1–85.1
NR
7.3–8.2 (4.9–5.8)
7.9 (SE 0.1)
96.9–97.5(18.8–19.0)
34 (5)
10 mcg BIDTZD +/− MET
a

Data presented are the range across treatment groups for mean and standard deviation.

Abbreviations: BID, twice daily; MET, metformin; SU, sulfonylurea; TZD, thiazolidinedione.

From: Results

Cover of Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus
Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report [Internet].
Norris SL, Lee NJ, Severance S, et al.
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.